Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of Foliglurax in Healthy Volunteers
NCT02639221Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Jan 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing PXT002331 with Placebo (2 arms). Primary endpoints: Number of Serious Adverse Events at 16 days and Number of clinically relevant signs or symptoms at 16 days. Started Jan 2016; status: completed.
02
Drugs
foliglurax
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02639221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639221.